Delving into the Latest Updates on Cantab Pharmaceuticals Plc with Synapse

概览

疾病领域	数量

感染	1
肿瘤	1

排名前五的药物类型	数量

重组亚单位疫苗	1

排名前五的靶点	数量

HPV E6 x HPV E7 x HPV L2	1

关联

1

项与 Cantab Pharmaceuticals Plc 相关的药物

Human papillomavirus vaccine TA-CIN(Xenova Ltd.)

靶点

HPV E6 x HPV E7 x HPV L2

作用机制

HPV E6抑制剂 [+3]

在研机构

Cancer Research Technology Ltd. [+3]

原研机构

Xenova Ltd.

在研适应症

外阴肿瘤 [+1]

非在研适应症

子宫颈发育不良 [+1]

最高研发阶段临床2期

首次获批国家/地区-

首次获批日期-

100 项与 Cantab Pharmaceuticals Plc 相关的临床结果

登录后查看更多信息

0 项与 Cantab Pharmaceuticals Plc 相关的专利（医药）

登录后查看更多信息

6

项与 Cantab Pharmaceuticals Plc 相关的文献（医药）

2002-01-01·Advances in Behavioral Biology

Quantitative Analysis and Behavioural Correlates of Lesioning of the Subthalamic Nucleus in the Hemiparkinsonian Marmoset

作者: S. B. Dunnett ; L. E. Annett ; E. M. Torres ; J. M. Henderson

The basal ganglia differs in size and structure between species. For example the striatum in the rat is not segregated into a distinct caudate nucleus and putamen as it is in primates (Brodal, 1981; Paxinos, 1995). Also, the rat homologue of the internal globus pallidus, the entopeduncular nucleus, is not located in the same position as it is in primates (Brodal, 1981; Paxinos, 1995). Such anatomical differences between species may result in differential effects of basal ganglia surgery or pharmacological manipulations when results from animals are extrapolated to human movement disorders.

2000-02-15·The Journal of Immunology2区 · 医学

Engagement of the OX-40 Receptor In Vivo Enhances Antitumor Immunity

2区 · 医学

Article

作者: Alvord, Gregory ; Vetto, John T. ; Weinberg, Andrew D. ; Urba, Walter J. ; Prell, Rodney ; Rivera, Martin-Muy ; Shields, John ; Bunce, Campbell ; Morris, Arden ; Ramstad, Trygg

AbstractThe OX-40 receptor (OX-40R), a member of the TNFR family, is primarily expressed on activated CD4+ T lymphocytes. Engagement of the OX-40R, with either OX-40 ligand (OX-40L) or an Ab agonist, delivers a strong costimulatory signal to effector T cells. OX-40R+ T cells isolated from inflammatory lesions in the CNS of animals with experimental autoimmune encephalomyelitis are the cells that respond to autoantigen (myelin basic protein) in vivo. We identified OX-40R+ T cells within primary tumors and tumor-invaded lymph nodes of patients with cancer and hypothesized that they are the tumor-Ag-specific T cells. Therefore, we investigated whether engagement of the OX-40R in vivo during tumor priming would enhance a tumor-specific T cell response. Injection of OX-40L:Ig or anti-OX-40R in vivo during tumor priming resulted in a significant improvement in the percentage of tumor-free survivors (20–55%) in four different murine tumors derived from four separate tissues. This anti-OX-40R effect was dose dependent and accentuated tumor-specific T cell memory. The data suggest that engagement of the OX-40R in vivo augments tumor-specific priming by stimulating/expanding the natural repertoire of the host’s tumor-specific CD4+ T cells. The identification of OX-40R+ T cells clustered around human tumor cells in vivo suggests that engagement of the OX-40R may be a practical approach for expanding tumor-reactive T cells and thereby a method to improve tumor immunotherapy in patients with cancer.

1998-04-01·Trends in Genetics

Gene therapy—the gutless approach pays off

作者: Whittle, N

Abstract Molecular and Cellular Biology of Gene Therapy, Keystone Symposium, Keystone, USA, 19–25 January 1998.

100 项与 Cantab Pharmaceuticals Plc 相关的药物交易

登录后查看更多信息

100 项与 Cantab Pharmaceuticals Plc 相关的转化医学

登录后查看更多信息